OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Zibelman on Combinations of Immunotherapy for RCC

October 30th 2017

Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy combinations in the treatment of patients with renal cell carcinoma (RCC).

Dr. Yardley Discusses CDK4/6 Inhibitors for Breast Cancer

October 30th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.

Dr. Pothuri on PARP Inhibitors for Ovarian Cancer

October 30th 2017

Bhavana Pothuri, MD, an associate professor in the Department of Obstetrics and Gynecology at NYU Langone's Perlmutter Cancer Center, discusses PARP inhibitors for the treatment of patients with ovarian cancer.

Dr. Brammer on Updates in the Treatment Landscape for T-Cell Lymphoma

October 30th 2017

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses updates in the treatment landscape of T-cell lymphoma.

Dr. Butler on the Importance of Health Literacy Initiatives

October 28th 2017

Thomas Butler, MD, associate professor of interdisciplinary clinical oncology, Mitchell Cancer Center, discusses the importance of health literacy initiatives at the Association of Community Cancer Center (ACCC) National Oncology Conference.

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

October 28th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

Dr. Melisko on the Role of Neoadjuvant Chemotherapy in ER+ Cancer

October 27th 2017

Michelle E. Melisko, MD, a clinical professor of medicine, University of California, San Francisco (UCSF), discusses the role of neoadjuvant chemotherapy in estrogen receptor (ER)-positive breast cancer.

Dr. Daniels Discusses Treatment Options in Thyroid Cancer

October 27th 2017

Gregory A. Daniels, MD, PhD, medical oncologist, associate professor of medicine, UC San Diego Health, discusses treatment options for patients with thyroid cancer.

Dr. van 't Veer on Guidelines for Genetic Testing in Breast Cancer

October 27th 2017

Laura van ’t Veer, PhD, Leader of the Breast Oncology Program, and director of Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the guidelines for genetic testing in breast cancer.

Dr. Barrett on Addressing Cancer Disparities

October 27th 2017

Nadine J. Barrett, PhD, Duke Cancer Institute, discusses the need to address cancer disparities during the Association of Community Cancer Centers (ACCC) 43rd Annual Meeting.

Dr. Rosko on Treatment for Elderly Patients With Multiple Myeloma

October 27th 2017

Ashley Rosko, MD, assistant professor in the Division of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses treatment for elderly patients with multiple myeloma.

Dr. Kim on the Need for EAPathways as a Decision-Making Tool

October 27th 2017

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses the need to develop EAPathways as an improved decision-making tool for oncologists during the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Dr. O'Regan on Biomarker Research in Breast Cancer

October 27th 2017

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.

Dr. Stone on MRD in Hematologic Malignancies

October 27th 2017

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses minimal residual disease (MRD) in hematologic malignancies.

Dr. Blau on a Research-Based Approach to Meet OCM Requirements

October 27th 2017

Sibel Blau, MD, medical oncology provider, medical director, Hematology/Oncology, Northwest Medical Specialties, discusses a value-based care model for oncology at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Dr. Ruiz on the HIV-Oncology Clinic Program

October 27th 2017

Marco Ruiz, MD, associate physician, Moffitt Cancer Center, discusses HIV-Oncology Clinic at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

October 26th 2017

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Dr. Brammer on Brentuximab Vedotin for Patients With T-Cell Lymphoma

October 26th 2017

Jonathan E. Brammer, MD, assistant professor of hematology, Ohio State University Comprehensive Cancer Center, discusses brentuximab vedotin (Adcetris) for patients with T-cell lymphoma.

Dr. Gandhi Discusses the Role of Alectinib in ALK+ Lung Cancer

October 26th 2017

Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses the role of alectinib (Alecensa) in patients with ALK-positive non-small cell lung cancer (NSCLC).

Dr. Hoffman-Censits Discusses the Future Treatment of Bladder Cancer

October 26th 2017

Jean Hoffman-Censits, MD, associate professor of Medical Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses the future treatment landscape of bladder cancer.